• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eyenovia unveils digital ocular drug delivery device

December 22, 2022 By Sean Whooley

Eyenovia microdose array print MAP ocular drug delivery device
[Image courtesy of Eyenovia]
Eyenovia (Nasdaq:EYEN) announced today that it is developing a microdosing system to facilitate the digital delivery of eye medications.

New York-based Eyenovia develops a pipeline of late-stage microdose array print (MAP) therapeutics. It aims for this system to improve the overall patient experience and streamline practice flow.

The investigational device showed promise in delivery cleaner and more efficient ocular drug delivery, according to a news release.

“The proprietary Eyenovia device takes a novel approach to administering eye medication via microdosing and does it in a way that should improve the patient experience,” said Michael Rowe, CEO of Eyenovia. “Traditional eye droppers are cumbersome, inaccurate, and prone to contamination. Even when handled with care, there’s still a significant likelihood that medication patients are paying for gets wasted due to missing drops.”

About the Eyenovia device

Eyenovia designed the device with no protruding parts and a recessed nozzle. This allows for no touching to the patients’ eyes, reducing the likelihood of infection.

Additionally, the company anticipates a more gentle dosing experience with the device. It said this could create a fundamental paradigm shift in eye care.

The company said eye drop innovation “has stagnated.” This comes as a result of changing medical device regulations, Eyenovia noted. It expects regulators to “keep pace with the cutting-edge new products” pushing the boundaries of digital technology.

“We’re proud to be innovating in this space where we have the potential to make lives easier for millions of Americans and people worldwide suffering from chronic eye conditions,” said Rowe.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Technology Tagged With: Eyenovia Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS